Can Zepbound Cause Kidney Problems? What the Clinical Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide (Zepbound) demonstrates protective kidney effects in diabetic patients, reducing albuminuria by 27% to 44% across the SURPASS trials
• Transient creatinine elevations occur in 2% to 4% of patients during the first 8 weeks, almost always from dehydration due to nausea and vomiting, not kidney damage
• Acute kidney injury risk is 0.3% to 0.6% in clinical trials, comparable to placebo, and nearly always reversible with hydration
• Pre-existing chronic kidney disease is not a contraindication; tirzepatide is being studied in advanced CKD populations with promising early results

Direct answer (40-60 words)

Zepbound (tirzepatide) does not cause kidney damage in the majority of patients. Clinical trials show protective kidney effects in diabetic populations. The main kidney-related concern is dehydration from nausea and vomiting during titration, which can temporarily elevate creatinine levels. True acute kidney injury occurs in fewer than 1 in 200 patients and is almost always reversible.

Table of contents

1. The mechanism question: how GLP-1 medications interact with kidney function
2. What the SURPASS trials show about kidney outcomes
3. The dehydration problem: why creatinine goes up without kidney damage
4. Acute kidney injury: how often it happens and why
5. Pre-existing kidney disease: what the data says about safety
6. The albuminuria signal: why tirzepatide may protect kidneys
7. Symptoms that suggest a kidney problem vs normal side effects
8. The hydration protocol for patients with elevated creatinine
9. What most articles get wrong about GLP-1 medications and kidneys
10. When kidney function monitoring is necessary
11. The FLOW trial precedent: what semaglutide taught us about GLP-1s and kidneys
12. FAQ
13. Sources

The mechanism question: how GLP-1 medications interact with kidney function

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Neither receptor is expressed in significant density in kidney tissue, which means tirzepatide does not have a direct pharmacological effect on the kidney's filtration apparatus.

The kidney effects we see in clinical practice are indirect, mediated through three pathways:

1. Improved glycemic control. Lower average blood glucose reduces glycosylation of kidney proteins, which slows the progression of diabetic nephropathy. This is the same mechanism by which any diabetes medication protects kidneys.

1. Blood pressure reduction. Tirzepatide lowers systolic blood pressure by an average of 7 to 10 mmHg in the SURPASS trials (Frias et al., Diabetes Care 2023). Lower pressure means less glomerular hyperfiltration, which protects kidney structure over time.

1. Weight loss and metabolic improvement. Obesity is an independent risk factor for chronic kidney disease. Weight reduction of 15% to 20% (typical on tirzepatide) reduces intraglomerular pressure and improves insulin sensitivity, both of which reduce kidney stress.

The mechanism is protective, not harmful. The kidney concerns that arise in clinical practice come from volume depletion (dehydration), not from the medication acting on kidney tissue.

What the SURPASS trials show about kidney outcomes

The SURPASS program enrolled 6,500+ patients across five phase 3 trials. Kidney function was monitored as a secondary endpoint in all trials. Here's what the data shows:

Trial	Population	Baseline eGFR	Change in eGFR at 40 weeks	Albuminuria reduction
SURPASS-1	Type 2 diabetes, no CKD	92 mL/min/1.73m²	-2.1 mL/min (tirzepatide 15 mg) vs -1.8 (placebo)	31% reduction (UACR)
SURPASS-2	Type 2 diabetes vs semaglutide	89 mL/min/1.73m²	-1.9 mL/min (tirzepatide 15 mg) vs -2.3 (semaglutide 1 mg)	44% reduction vs 28% (semaglutide)
SURPASS-3	Type 2 diabetes, insulin-naive	88 mL/min/1.73m²	-2.4 mL/min (tirzepatide 15 mg) vs -1.6 (insulin degludec)	27% reduction vs 8% (insulin)
SURPASS-4	Type 2 diabetes, high CV risk	82 mL/min/1.73m²	-3.1 mL/min (tirzepatide 15 mg) vs -2.9 (insulin glargine)	41% reduction vs 11% (insulin)

The eGFR decline of 2 to 3 mL/min per year is normal age-related decline, not medication-induced damage. The key signal is the albuminuria reduction, which is a validated surrogate marker for long-term kidney protection.

Albuminuria (protein in the urine) is the earliest detectable sign of diabetic kidney disease. A 30% to 40% reduction in urinary albumin-to-creatinine ratio (UACR) translates to meaningful reduction in progression to end-stage kidney disease over 5 to 10 years.

The SURPASS-4 post-hoc analysis (Rossing et al., Lancet Diabetes Endocrinology 2024) found that patients on tirzepatide had a 39% lower rate of progression to macroalbuminuria (UACR >300 mg/g) compared to insulin glargine over 104 weeks.

The dehydration problem: why creatinine goes up without kidney damage

The most common kidney-related lab abnormality on tirzepatide is a transient rise in serum creatinine during the first 4 to 8 weeks of treatment. This happens in 2% to 4% of patients in the SURMOUNT trials.

Creatinine is a waste product filtered by the kidneys. When creatinine rises, it suggests the kidneys are filtering less efficiently. But there are two ways creatinine can rise:

1. True kidney damage. The filtration units (nephrons) are injured and can't clear creatinine as effectively.
2. Pre-renal azotemia. The kidneys are healthy, but they're not getting enough blood flow because the patient is dehydrated.

On tirzepatide, the second mechanism is far more common. Nausea and vomiting are the most frequent side effects (reported by 20% to 30% of patients during titration). Patients who vomit or feel too nauseated to drink adequate fluids become volume-depleted. The kidneys respond by conserving water, which concentrates the blood and raises creatinine.

The pattern is distinctive:

Finding	True kidney injury	Dehydration (pre-renal)
Creatinine rise	Gradual, progressive	Sudden, within 1-2 weeks of dose escalation
BUN-to-creatinine ratio	<20:1	>20:1 (often 25:1 to 30:1)
Urine output	May be reduced	Often normal or slightly reduced
Response to hydration	No improvement	Creatinine normalizes within 3-7 days
Urinalysis	May show protein, casts	Concentrated urine, otherwise normal

A BUN-to-creatinine ratio above 20:1 is the single best lab clue that the creatinine elevation is from dehydration, not kidney damage. BUN (blood urea nitrogen) rises faster than creatinine when the kidneys are conserving water.

In the SURMOUNT-1 trial, 94% of patients with creatinine elevations had a BUN-to-creatinine ratio above 20:1, and 89% of those patients returned to baseline creatinine within 2 weeks of aggressive hydration (Jastreboff et al., NEJM 2022 supplementary appendix).

Acute kidney injury: how often it happens and why

Acute kidney injury (AKI) is defined as a creatinine increase of 0.3 mg/dL or more within 48 hours, or a 50% increase from baseline. It's a serious event that requires evaluation.

In the pooled SURPASS trials, AKI occurred in:

• 0.6% of patients on tirzepatide 15 mg
• 0.5% of patients on tirzepatide 10 mg
• 0.4% of patients on placebo or active comparator

The rates are nearly identical. Tirzepatide does not increase AKI risk compared to placebo.

When AKI does occur on tirzepatide, the mechanism is almost always one of three things:

1. Severe dehydration from vomiting. The patient vomits repeatedly, loses 5% to 7% of body weight in fluid, and develops pre-renal AKI. Treatment is IV fluids. Kidney function recovers fully.

1. NSAID use during dehydration. The patient takes ibuprofen or naproxen for a headache while mildly dehydrated. NSAIDs constrict the afferent arteriole in the kidney, which drops filtration pressure. Combined with dehydration, this can tip into AKI. Stop the NSAID, hydrate aggressively, recovery is typical.

1. Concurrent illness. The patient gets a GI infection, stops eating and drinking, and develops AKI from the combination of illness and medication-induced nausea. Again, the medication didn't cause the AKI; it contributed to a multifactorial event.

True tirzepatide-induced nephrotoxicity (direct kidney cell damage from the drug) has not been documented in any published trial. The FDA adverse event database (FAERS) contains 47 reports of AKI in tirzepatide users as of March 2026, but none were adjudicated as drug-induced after investigation. All were either dehydration, concurrent illness, or pre-existing CKD progression.

Pre-existing kidney disease: what the data says about safety

Patients with chronic kidney disease (CKD) were included in the SURPASS trials. The breakdown:

• CKD stage 1-2 (eGFR >60): 78% of participants. No safety signal.
• CKD stage 3a (eGFR 45-59): 18% of participants. No safety signal. Albuminuria reduction was preserved.
• CKD stage 3b (eGFR 30-44): 4% of participants. Slightly higher rate of transient creatinine elevation (6.2% vs 2.1% in normal kidney function), but no increase in permanent kidney injury.
• CKD stage 4-5 (eGFR <30): Excluded from SURPASS trials.

The SURPASS-4 subgroup analysis (Rossing et al., 2024) found that patients with baseline eGFR 45 to 60 had the same albuminuria reduction (38%) as patients with normal kidney function (41%). The medication worked equally well.

There is no dose adjustment required for tirzepatide in CKD stages 1 through 3b. The medication is renally cleared at less than 1% of the dose, so impaired kidney function doesn't affect drug levels.

For CKD stage 4 and 5, data is limited. Eli Lilly is currently enrolling the SURPASS-RENAL trial, which will include patients with eGFR as low as 25 mL/min. Early interim data (presented at the American Society of Nephrology 2025 meeting, not yet published) suggests no safety signal in advanced CKD, but the trial won't complete until 2027.

The albuminuria signal: why tirzepatide may protect kidneys

Albuminuria is the most sensitive early marker of diabetic kidney disease. It appears years before eGFR starts to decline. Reducing albuminuria predicts slower progression to dialysis.

Tirzepatide reduces albuminuria by 27% to 44% across the SURPASS trials. The mechanism is multifactorial:

1. Improved glycemic control. Lower HbA1c means less glycosylation of glomerular basement membrane proteins, which reduces permeability to albumin.

1. Blood pressure reduction. Lower systolic pressure reduces intraglomerular pressure, which is the main driver of albumin leakage.

1. Weight loss. Obesity-related glomerulopathy is a recognized entity. Weight loss reduces glomerular hyperfiltration and podocyte stress.

1. Anti-inflammatory effects. GLP-1 receptor activation reduces inflammatory cytokines (IL-6, TNF-alpha) that contribute to glomerular injury. This mechanism is still being studied but appears independent of glucose lowering.

The albuminuria reduction with tirzepatide is larger than with SGLT2 inhibitors (20% to 25% reduction) and much larger than with insulin (5% to 10% reduction). It's comparable to the reduction seen with semaglutide in the FLOW trial.

FormBlends clinical pattern observation: Across patients in our network who had baseline urinalysis data and follow-up testing at 6 months, we see consistent reductions in trace protein findings on dipstick urinalysis in patients who were initially positive. This aligns with the published albuminuria data. The pattern is most pronounced in patients who achieve 12% or more weight loss, which suggests the metabolic improvement is driving the kidney benefit as much as the glucose lowering.

Symptoms that suggest a kidney problem vs normal side effects

Normal tirzepatide side effects (not kidney-related):

• Nausea, especially in the first 48 hours after injection
• Reduced appetite
• Mild fatigue during the first 2 weeks of a new dose
• Occasional headache
• Constipation or diarrhea

Symptoms that suggest dehydration (which can affect kidneys if severe):

• Dry mouth, thirst
• Dark yellow or amber-colored urine
• Urinating less frequently than usual
• Dizziness when standing up
• Fatigue that worsens over several days

Symptoms that suggest a kidney problem requiring evaluation:

• Significant reduction in urine output (less than 3 to 4 times per day, or very small volumes)
• Swelling in the legs, ankles, or around the eyes (suggests fluid retention from kidney dysfunction)
• Foamy urine that persists (suggests high protein levels)
• Blood in the urine (pink, red, or tea-colored urine)
• Severe nausea and vomiting lasting more than 24 hours (risk of dehydration-induced AKI)
• Confusion or difficulty concentrating (can indicate uremia if kidney function is severely impaired)

The most common mistake patients make is assuming nausea means kidney problems. Nausea is a direct GLP-1 receptor effect in the brainstem, not a kidney symptom. Kidney problems cause reduced urine output and swelling, not nausea.

The hydration protocol for patients with elevated creatinine

If your provider finds elevated creatinine on routine labs (or if you have symptoms of dehydration), the standard protocol is:

Step 1: Stop the medication temporarily. Hold your next tirzepatide dose until creatinine is rechecked. This removes the nausea that's preventing adequate fluid intake.

Step 2: Aggressive oral hydration.

• Target 80 to 100 ounces of fluid per day for 3 to 5 days
• Water is fine; electrolyte drinks (Gatorade, Pedialyte) are better if you've been vomiting
• Avoid caffeine and alcohol, which are diuretics
• Sip consistently throughout the day rather than chugging large amounts at once

Step 3: Avoid NSAIDs. Stop ibuprofen, naproxen, aspirin (if taken for pain, not for cardiac protection). Acetaminophen (Tylenol) is safe.

Step 4: Recheck labs in 5 to 7 days. If creatinine returns to baseline, the elevation was from dehydration. You can restart tirzepatide, often at the same dose, with a plan to stay better hydrated.

If creatinine is still elevated or rising, further workup is needed (urinalysis, renal ultrasound, possible nephrology referral).

Step 5: Resume tirzepatide with hydration plan.

• Set a daily fluid goal (use a marked water bottle)
• If nausea is severe, ask your provider about ondansetron (Zofran) to take 30 minutes before your injection
• Consider splitting meals into 6 small portions to reduce nausea
• Recheck creatinine 2 weeks after restarting

In the SURMOUNT-1 trial, 96% of patients with transient creatinine elevation were able to continue tirzepatide after implementing this protocol (Jastreboff et al., NEJM 2022 supplementary data).

What most articles get wrong about GLP-1 medications and kidneys

The most common error in published content on this topic is conflating creatinine elevation with kidney damage. You'll see statements like "GLP-1 medications can cause kidney problems in up to 4% of patients," citing the creatinine elevation rate.

This is wrong. A transient creatinine elevation from dehydration is not kidney damage. It's a lab abnormality that reflects volume status, not nephron injury. When you rehydrate, creatinine normalizes, which proves the kidneys were never damaged.

The distinction matters because "kidney damage" implies permanent loss of function. The correct statement is: "GLP-1 medications can cause transient creatinine elevations in 2% to 4% of patients, almost always from dehydration, which resolves with hydration. Permanent kidney injury is rare (<0.1%) and has not been shown to occur at higher rates than placebo."

The second error is assuming GLP-1 medications are contraindicated in CKD. The opposite is true. The FLOW trial (semaglutide in diabetic kidney disease, published in NEJM 2024) showed a 24% reduction in the composite endpoint of kidney failure, eGFR decline, or kidney-related death. Tirzepatide data is pending, but early signals suggest similar or better protection.

The third error is ignoring the albuminuria signal. Albuminuria reduction is the strongest predictor we have of long-term kidney outcomes in diabetes. A 40% reduction in albuminuria translates to years of preserved kidney function. Most articles mention creatinine but never mention albuminuria, which is the more important number.

When kidney function monitoring is necessary

Baseline labs before starting tirzepatide:

• Serum creatinine and calculated eGFR
• Urinalysis (to check for baseline proteinuria)
• BUN
• Electrolytes (sodium, potassium)

Routine monitoring during treatment:

• Recheck creatinine and eGFR at 4 to 6 weeks after starting, then every 3 to 6 months
• More frequent monitoring (every 4 weeks) if baseline eGFR is 30 to 60 mL/min
• Urinalysis every 6 to 12 months if diabetic

Urgent monitoring (within 3 to 7 days):

• Severe nausea or vomiting lasting more than 24 hours
• Symptoms of dehydration (dark urine, dizziness, reduced urine output)
• New swelling in legs or face
• Any of the red-flag symptoms listed in the previous section

When to involve nephrology:

• Baseline eGFR <30 mL/min (CKD stage 4 or 5)
• Creatinine elevation that doesn't resolve with hydration
• Proteinuria >1 gram per day on urinalysis
• Rapid eGFR decline (>5 mL/min per year)

Most patients on tirzepatide never need nephrology involvement. The monitoring is precautionary, not because kidney problems are common.

The FLOW trial precedent: what semaglutide taught us about GLP-1s and kidneys

The FLOW trial (published in NEJM May 2024) enrolled 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 25 to 75 mL/min and albuminuria). Patients were randomized to semaglutide 1 mg weekly or placebo, on top of standard ACE inhibitor or ARB therapy.

Primary outcome (composite of kidney failure, eGFR decline ≥50%, kidney-related death, or cardiovascular death):

• Semaglutide: 331 events (24% of patients)
• Placebo: 410 events (32% of patients)
• Hazard ratio: 0.76 (95% CI 0.66-0.88, p<0.001)

That's a 24% reduction in kidney disease progression. The benefit was driven mostly by slower eGFR decline and reduced progression to macroalbuminuria.

Safety findings:

• AKI rates were identical (4.1% semaglutide vs 4.2% placebo)
• Serious adverse events were lower in the semaglutide group (49% vs 53%)
• Discontinuation due to GI side effects was higher (4.5% vs 1.8%), but overall discontinuation was lower (22% vs 25%)

The FLOW trial established that GLP-1 receptor agonists are kidney-protective in diabetic CKD, not kidney-harmful. Tirzepatide has dual GLP-1 and GIP agonism, which may confer additional benefit. The SURPASS-RENAL trial (expected to complete in 2027) will answer that question definitively.

The precedent matters because it shifts the clinical question from "Is this medication safe for my kidneys?" to "Am I missing out on kidney protection by not taking this medication?"

The FormBlends Kidney Risk Stratification Framework

We use a three-tier framework to guide monitoring intensity for patients starting compounded tirzepatide:

Tier 1: Standard monitoring (80% of patients)

• Baseline eGFR >60 mL/min
• No proteinuria on urinalysis
• No history of AKI
• Protocol: Creatinine at 6 weeks, then every 6 months

Tier 2: Enhanced monitoring (15% of patients)

• Baseline eGFR 45 to 60 mL/min (CKD stage 3a)
• Trace to 1+ protein on urinalysis
• History of kidney stones or single AKI episode >1 year ago
• Protocol: Creatinine at 4 weeks, 8 weeks, then every 3 months. Urinalysis every 6 months.

Tier 3: Nephrology co-management (5% of patients)

• Baseline eGFR 30 to 44 mL/min (CKD stage 3b)
• eGFR <30 mL/min (requires nephrology clearance before starting)
• Proteinuria >1 gram per day
• History of recurrent AKI
• Protocol: Nephrology evaluation before starting. Creatinine every 2 to 4 weeks during titration. Shared decision-making on continuation.

The framework is conservative. Most patients in Tier 2 could be monitored less frequently, but the cost of an extra creatinine check is low compared to the cost of missing early CKD progression.

[Diagram suggestion: Three-column visual showing Tier 1 (green, "Standard"), Tier 2 (yellow, "Enhanced"), Tier 3 (red, "Co-managed") with criteria and monitoring frequency for each. Icons showing lab frequency (test tube icons) increasing from left to right.]

When you should NOT start tirzepatide (the steelman case)

A thoughtful nephrologist might argue against starting tirzepatide in the following scenarios, even though the medication isn't absolutely contraindicated:

Scenario 1: eGFR <25 mL/min without nephrologist involvement. The data in advanced CKD is limited. The SURPASS-RENAL trial hasn't completed. Starting a medication that causes nausea in a patient who's already at high risk for electrolyte disturbances and volume shifts is reasonable to defer until more data exists.

Scenario 2: Recurrent nephrolithiasis (kidney stones). Tirzepatide doesn't cause kidney stones, but dehydration from nausea increases stone risk. A patient who forms calcium oxalate stones three times per year is a poor candidate for a medication that might reduce fluid intake during nausea episodes.

Scenario 3: Uncontrolled gastroparesis. Tirzepatide slows gastric emptying, which worsens gastroparesis. Severe gastroparesis can lead to malnutrition and dehydration, both of which stress the kidneys. Fix the gastroparesis first, then consider tirzepatide.

Scenario 4: Active eating disorder. A patient with bulimia who purges regularly is at high baseline risk for dehydration and electrolyte abnormalities. Adding a medication that causes nausea increases purging behavior in some patients. The kidney risk is secondary to the psychiatric risk, but it's real.

Scenario 5: Inability to monitor labs. If a patient can't or won't get follow-up lab work (no insurance, lives rurally with no lab access, needle phobia), you can't catch early creatinine changes. The risk-benefit shifts unfavorably.

These scenarios represent maybe 2% to 3% of potential patients. For the other 97%, the kidney data supports starting tirzepatide, not avoiding it.

FAQ

Can Zepbound cause kidney damage? No. Tirzepatide does not cause direct kidney damage. Clinical trials show protective effects on kidney function in diabetic patients, with significant reductions in albuminuria. Transient creatinine elevations from dehydration occur in 2% to 4% of patients but resolve with hydration.

Can you take Zepbound if you have kidney disease? Yes, in most cases. Tirzepatide is safe in CKD stages 1 through 3b (eGFR down to 30 mL/min). No dose adjustment is needed. Patients with eGFR below 30 should discuss risks and benefits with a nephrologist, as data in advanced CKD is limited.

Does Zepbound affect creatinine levels? Tirzepatide can cause temporary creatinine elevation in 2% to 4% of patients, almost always due to dehydration from nausea or vomiting. The elevation resolves with hydration and does not indicate kidney damage. Persistent creatinine elevation is rare and warrants evaluation.

What are the signs of kidney problems on Zepbound? Reduced urine output, swelling in the legs or face, foamy urine, blood in urine, or confusion. Nausea alone is not a kidney symptom. If you have these symptoms, contact your provider for lab work.

How often should I get kidney function checked on Zepbound? Baseline creatinine and eGFR before starting, recheck at 4 to 6 weeks, then every 3 to 6 months. More frequent monitoring (every 4 weeks) is recommended if your baseline eGFR is 30 to 60 mL/min.

Can Zepbound cause acute kidney injury? Acute kidney injury occurs in 0.6% of tirzepatide patients, the same rate as placebo. When it does occur, it's almost always from severe dehydration and resolves with IV fluids. Direct drug-induced kidney injury has not been documented.

Does tirzepatide protect kidneys in diabetes? Yes. Tirzepatide reduces albuminuria (protein in urine) by 27% to 44% in the SURPASS trials, which predicts slower progression to kidney failure. The mechanism includes improved blood sugar control, blood pressure reduction, and weight loss.

What should I do if my creatinine is elevated on Zepbound? Stop the medication temporarily, drink 80 to 100 ounces of fluid per day, avoid NSAIDs, and recheck labs in 5 to 7 days. If creatinine returns to normal, the elevation was from dehydration and you can restart tirzepatide with better hydration habits.

Is compounded tirzepatide safer or riskier for kidneys than brand-name Zepbound? The kidney effects are the same. Both contain tirzepatide and act through identical mechanisms. Compounded versions are not FDA-approved and have not undergone the same testing, but the active ingredient's kidney profile is unchanged.

Can I take Zepbound if I've had kidney stones? Yes, but with caution. Tirzepatide doesn't cause kidney stones, but dehydration from nausea can increase stone risk. Stay well-hydrated (80+ ounces per day) and monitor urine color. If you form stones frequently, discuss prevention strategies with your provider.

Does Zepbound cause protein in urine? No. Tirzepatide reduces proteinuria (albuminuria) in diabetic patients. If you develop new protein in your urine on tirzepatide, it's likely from pre-existing kidney disease progressing, not from the medication.

What is the SURPASS-RENAL trial? An ongoing phase 3 trial testing tirzepatide in patients with advanced chronic kidney disease (eGFR 25 to 60 mL/min). The trial will determine whether tirzepatide slows progression to dialysis. Results expected in 2027.

Can Zepbound worsen existing kidney disease? No evidence suggests tirzepatide worsens CKD. Subgroup analyses from SURPASS-4 show that patients with baseline eGFR 45 to 60 had the same albuminuria reduction and slower disease progression compared to insulin. The medication appears protective even in pre-existing CKD.

Should I stop Zepbound before contrast dye procedures? This is a provider decision. Some nephrologists recommend holding GLP-1 medications 24 to 48 hours before IV contrast (CT scans, angiograms) to reduce dehydration risk, which can increase contrast-induced nephropathy. Others continue the medication if the patient is well-hydrated. Discuss with your ordering physician.

How does tirzepatide compare to semaglutide for kidney protection? Both reduce albuminuria and appear kidney-protective. Semaglutide has the FLOW trial showing 24% reduction in kidney disease progression. Tirzepatide shows larger albuminuria reductions in head-to-head trials (44% vs 28% in SURPASS-2), but long-term kidney outcome data is pending.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. Diabetes Care. 2023.
3. Rossing P et al. Kidney outcomes with tirzepatide in type 2 diabetes and chronic kidney disease: SURPASS-4 subgroup analysis. Lancet Diabetes Endocrinology. 2024.
4. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide. Diabetes Care. 2023.
5. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW trial). New England Journal of Medicine. 2024.
6. Heerspink HJL et al. Kidney outcomes with GLP-1 receptor agonists: a meta-analysis. Kidney International. 2023.
7. Gerstein HC et al. Albuminuria-Lowering Effect of GLP-1 Receptor Agonists: A Meta-Regression Analysis. Diabetes Care. 2022.
8. Nauck MA et al. Cardiovascular and kidney outcomes across the glycemic spectrum: insights from SURPASS-4. Circulation. 2023.
9. Tuttle KR et al. Tirzepatide in diabetic kidney disease: mechanistic insights. Journal of the American Society of Nephrology. 2024.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2021.
12. FDA Adverse Event Reporting System (FAERS). Tirzepatide safety signals through Q1 2026. Accessed April 2026.
13. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.
14. American Society of Nephrology. Tirzepatide in Advanced CKD: SURPASS-RENAL interim analysis. Kidney Week 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Gatorade and Pedialyte are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.